NEA invests in promising companies across the biopharma spectrum, at all stages of development. Early-stage innovation and strategic shifts by major pharmaceutical companies are creating tremendous opportunities to develop transformational and proprietary solutions to unmet medical needs. Fueled by an increasingly large talent pool and a strong demand for products, the result is fertile ground for building companies that will create significant long-term value and improve patients’ lives. We focus on novel therapeutics in major disease areas, with selected investments in diagnostics and platforms to optimize patient therapy and drug discovery, development and delivery.
total featured companies )